HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

February 1, 2032

Study Completion Date

February 2, 2032

Conditions
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
Interventions
DRUG

Ruxolitinib

oral

DRUG

Venetoclax

oral

DRUG

Dexamethasone

oral/intravenous

DRUG

Cyclophosphamide

intravenous

DRUG

Cytarabine

intravenous

DRUG

intrathecal chemotherapy

IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement

Trial Locations (33)

1090

NOT_YET_RECRUITING

St. Anna Kinderspital, Vienna

9000

NOT_YET_RECRUITING

Universitair Ziekenhuis Gent, Ghent

10126

NOT_YET_RECRUITING

Ospedale Infantile Regina Margherita, Turin

13005

NOT_YET_RECRUITING

Hopital La Timone - Enfants, Marseille

13353

RECRUITING

Charité Universitätsmedizin Berlin, Berlin

16147

NOT_YET_RECRUITING

IRCCS Istituto Giannina Gaslini, Genova

20900

NOT_YET_RECRUITING

Fondazione MBBM c/o Centro ML Verga, Monza

28009

NOT_YET_RECRUITING

Hospital Infantil Universitario Niño Jesús, Madrid

33076

NOT_YET_RECRUITING

Hôpital des Enfants GH Pellegrin - CHU de Bordeaux, Bordeaux

35128

NOT_YET_RECRUITING

Padova Azienda Ospedaliera, Padua

44093

NOT_YET_RECRUITING

CHU Nantes Hôpital Mère-Enfant, Nantes

45147

NOT_YET_RECRUITING

Universitätsklinikum Essen, Essen

46026

NOT_YET_RECRUITING

La Fe, Valencia

48149

NOT_YET_RECRUITING

Universitätsklinikum Münster, Münster

52621

NOT_YET_RECRUITING

Sheba Medical Center Hospital, Ramat Gan

59037

NOT_YET_RECRUITING

CHRU Lille - Hôpital Jeanne de Flandre, Lille

60590

NOT_YET_RECRUITING

Universitätsklinikum Frankfurt, Frankfurt

75019

NOT_YET_RECRUITING

Hôpital Robert Debré, Paris

86156

NOT_YET_RECRUITING

Universitätsklinikum Augsburg, Augsburg

4920235

NOT_YET_RECRUITING

Schneider's Children's Medical Center, Petah Tikva

DK-2100

RECRUITING

Rigshospitalet Copenhagen, Copenhagen

FI00029

NOT_YET_RECRUITING

Helsinki University Hospital, New Children's Hospital, Helsinki

69 373

NOT_YET_RECRUITING

Centre Léon Bérard, Lyon

D12N512

NOT_YET_RECRUITING

Our Lady's Hospital for Sick Children, Dublin

0165

NOT_YET_RECRUITING

Ospedale Pediatrico Bambino Gesù, IRCCS, Roma

3584CS

NOT_YET_RECRUITING

Princess Máxima Center for Pediatric Oncology, Utrecht

0373

NOT_YET_RECRUITING

Oslo University Hospital, Oslo

08950

NOT_YET_RECRUITING

Hospital Sant Joan de Déu de Barcelona, Barcelona

171 76

RECRUITING

Karolinska university hospital, Stockholm

B52 8BJ

NOT_YET_RECRUITING

Bristol Royal Hospital for Children, Bristol

WC1N 2BH

NOT_YET_RECRUITING

Great Ormond Street Hospital for Children NHS Trust, London

NE1 4LP

NOT_YET_RECRUITING

Great North Children's Hospital, Newcastle

SM2 5PT

NOT_YET_RECRUITING

Royal Marsden NHS Trust, Sutton

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Innovative Therapies For Children with Cancer Consortium

OTHER

collaborator

IBFM

INDUSTRY

collaborator

Fight Kids Cancer

OTHER

lead

Princess Maxima Center for Pediatric Oncology

OTHER

NCT05745714 - HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | Biotech Hunter | Biotech Hunter